Showing 1981-1990 of 2526 results for "".
- CDC Calls for Masks in Schools, Hard-Hit Areas, Even if Vaccinatedhttps://modernod.com/news/cdc-calls-for-masks-in-schools-hard-hit-areas-even-if-vaccinated/2479417/The Centers for Disease Control and Prevention (CDC) once again is recommending that some Americans wear masks indoors. The agency called today for masks in K-12 school settings and in areas of the United States experiencing high or substantial SARS-CoV-2 transmission, even for the fully vaccinat
- Harrow Health Granted Two Patents for Novel Surgical Dilation Formulationhttps://modernod.com/news/harrow-health-granted-two-patents-for-novel-surgical-dilation-formulation/2479377/Harrow Health announced that the United States Patent and Trademark Office issued two patents, entitled “Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof.” Harrow Health’s wholly owned subsidiary, ImprimisRx, provides surgical dilation (
- iSTAR Medical Receives FDA Approval to Begin Trial for MINIject for Patients With Glaucomahttps://modernod.com/news/istar-medical-receives-fda-approval-to-begin-trial-for-miniject-for-patients-with-glaucoma/2479375/iSTAR Medical announced that the FDA granted it investigational device exemption (IDE) to start a trial with MINIject. The STAR-V study will investigate MINIject in over 350 patients with primary open-angle glaucoma. Glaucoma surgeons in the United States, Canada, and Europe will join the trial.<
- Nicox Appoints Robert N. Weinreb, MD, and Sanjay G. Asrani, MD, to its Glaucoma Clinical Advisory Boardhttps://modernod.com/news/nicox-appoints-robert-n-weinreb-md-and-sanjay-g-asrani-md-to-its-glaucoma-clinical-advisory-board/2479362/Nicox SA announced that two internationally recognized experts in glaucoma, Robert N. Weinreb, MD, Distinguished Professor and Chair, Ophthalmology and Director, Shiley Eye Institute, University of California San Diego; and Sanjay G. Asrani, MD, Professor of Ophthalmology, Duke University, will b
- AMA Assigns CPT Code to Software Designed to Treat Adult Amblyopia (Lazy Eye)https://modernod.com/news/ama-assigns-cpt-code-to-software-designed-to-treat-adult-amblyopia-lazy-eye/2479361/RevitalVision announced that its standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical
- Belkin Laser Announces Corporate Name Change to Belkin Visionhttps://modernod.com/news/belkin-laser-announces-corporate-name-change-to-belkin-vision/2479352/Israel-based medical device company Belkin Laser announced that it will begin operating under the new name of Belkin Vision. The name change is a strategic decision that will better reflect the company’s capability to solve future ophthalmic challenges, according to a company stateme
- “Love Your Eyes” Theme of 2021 World Sight Dayhttps://modernod.com/news/love-your-eyes-theme-of-2021-world-sight-day/2479345/The International Agency for the Prevention of Blindness (IAPB) and its members are calling on everyone to focus on their eye health in a global campaign – #LoveYourEyes. The theme and materials are being launched on July 6 to mark 100 days to go until World Sight Day on October 14.
- GenSight Biologics Reports Topline Results From REFLECT Phase 3 Trial, Confirming Lumevoq Efficacyhttps://modernod.com/news/gensight-biologics-reports-topline-results-from-reflect-phase-3-trial-confirming-lumevoq-efficacy/2479336/GenSight Biologics reported key efficacy and safety findings at 1.5 years (78 weeks) post-treatment in the REFLECT phase 3 clinical trial for Lumevoq. The results show better visual acuity improvements from bilateral intravitreal injections of the gene therapy compared to a unilateral injection.<
- Ocular Therapeutix and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry AMDhttps://modernod.com/news/ocular-therapeutix-and-mosaic-biosciences-enter-into-strategic-discovery-collaboration-targeting-the-treatment-of-dry-age-related-macular-degeneration/2479331/Ocular Therapeutix entered into a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents aimed at the treatment of dry age-related macular degeneration (AMD). Ocular Therapeutix has agreed to fund the research performed under the collaboration and re
- FDA Accepts Application for Genentech’s Port Delivery System with Ranibizumab (PDS) for Treatment of Wet AMDhttps://modernod.com/news/fda-accepts-application-for-genentechs-port-delivery-system-with-ranibizumab-pds-for-treatment-of-wet-amd/2479322/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). If approved, PDS would be a first-of-its-kind therapeutic approa